Form 4: Summit Therapeutics Director Jeff Huber Acquires Shares in Private Placement

Director Jeff Huber acquired 44,052 shares of Summit Therapeutics Inc. common stock through a private placement via Caspian Capital LLC.

Summary

• Jeff Huber, a director of Summit Therapeutics Inc., acquired 44,052 shares of common stock on September 11, 2024.
• The shares were acquired through a private placement transaction via Caspian Capital LLC at a price of $22.70 per share.
• Huber is a manager and member of Caspian Capital LLC.
• Huber also indirectly owns 6,000 shares through an Estate Plan Living Trust, but disclaims beneficial ownership except to the extent of his pecuniary interest.
• The transaction closed on September 13, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. A director purchasing shares suggests confidence, but it's a routine filing related to a previously announced private placement.

Positives

• Director's investment may signal confidence in the company's future prospects.

Industry Context

Directors purchasing shares in their own company is generally viewed positively by the market, as it aligns management's interests with those of shareholders.

Related Party Transactions

• The acquisition of shares through Caspian Capital LLC, where Jeff Huber is a manager and member, constitutes a related party transaction.

Stakeholder Impact

• The transaction could positively influence shareholder sentiment due to the director's increased investment.

Key Dates